MannKind Corp (MNKD) - Financial and Strategic SWOT Analysis Review
Description
MannKind Corp (MNKD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
MannKind Corp (MannKind) is a biopharmaceutical company primarily engaged in the development and commercialization of inhaled therapeutic products and devices. The company's main focus is on addressing unmet medical needs for patients with endocrine and orphan lung diseases. MannKind's major offerings include dry-powder formulations and inhalation devices, designed to deliver medicines rapidly and conveniently to the deep lung. Its technologies are used in the treatment of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Its flagship product, Afrezza is a rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type-2 diabetes. Mannkind has manufacturing facility in Danbury, Connecticut and sells products to wholesale distributors and specialty pharmacies in the US. MannKind is headquartered in Westlake Village, California, the US.
MannKind Corp Key Recent Developments
Mar 04,2026: MannKind to Participate in Upcoming Investor Conferences
Feb 26,2026: MannKind Reports Fourth-Quarter and Full-Year 2025 Financial Results and Business Update
Feb 19,2026: MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Jan 26,2026: MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance When Switching From Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
MannKind Corp (MannKind) is a biopharmaceutical company primarily engaged in the development and commercialization of inhaled therapeutic products and devices. The company's main focus is on addressing unmet medical needs for patients with endocrine and orphan lung diseases. MannKind's major offerings include dry-powder formulations and inhalation devices, designed to deliver medicines rapidly and conveniently to the deep lung. Its technologies are used in the treatment of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Its flagship product, Afrezza is a rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type-2 diabetes. Mannkind has manufacturing facility in Danbury, Connecticut and sells products to wholesale distributors and specialty pharmacies in the US. MannKind is headquartered in Westlake Village, California, the US.
MannKind Corp Key Recent Developments
Mar 04,2026: MannKind to Participate in Upcoming Investor Conferences
Feb 26,2026: MannKind Reports Fourth-Quarter and Full-Year 2025 Financial Results and Business Update
Feb 19,2026: MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Jan 26,2026: MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance When Switching From Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
53 Pages
- Section 1 - About the Company
- MannKind Corp - Key Facts
- MannKind Corp - Key Employees
- MannKind Corp - Key Employee Biographies
- MannKind Corp - Major Products and Services
- MannKind Corp - History
- MannKind Corp - Company Statement
- MannKind Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- MannKind Corp - Business Description
- R&D Overview
- MannKind Corp - Corporate Strategy
- MannKind Corp - SWOT Analysis
- SWOT Analysis - Overview
- MannKind Corp - Strengths
- MannKind Corp - Weaknesses
- MannKind Corp - Opportunities
- MannKind Corp - Threats
- MannKind Corp - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- MannKind Corp, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- MannKind Corp, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Mar 04, 2026: MannKind to Participate in Upcoming Investor Conferences
- Feb 26, 2026: MannKind Reports Fourth-Quarter and Full-Year 2025 Financial Results and Business Update
- Feb 19, 2026: MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Jan 26, 2026: MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance When Switching From Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
- Jan 08, 2026: MannKind Business Updates and 2026 Growth Drivers
- Dec 23, 2025: MannKind Announces FUROSCIX Business Updates
- Nov 10, 2025: MannKind Discontinues Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
- Oct 13, 2025: MannKind Receives FDA Acceptance for Afrezza Application for Pediatric Diabetes Treatment
- Oct 07, 2025: MannKind Completes Acquisition of scPharmaceuticals to Enhance Revenue in Cardiometabolic Care
- Sep 29, 2025: MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- MannKind Corp, Key Facts
- MannKind Corp, Key Employees
- MannKind Corp, Key Employee Biographies
- MannKind Corp, Major Products and Services
- MannKind Corp, History
- MannKind Corp, Subsidiaries
- MannKind Corp, Key Competitors
- MannKind Corp, Ratios based on current share price
- MannKind Corp, Annual Ratios
- MannKind Corp, Annual Ratios (Cont...1)
- MannKind Corp, Annual Ratios (Cont...2)
- MannKind Corp, Interim Ratios
- MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- MannKind Corp, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- MannKind Corp, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- MannKind Corp, Performance Chart (2021 - 2025)
- MannKind Corp, Ratio Charts
- MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
